Published in Am J Physiol Renal Physiol on December 30, 2009
mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest (2011) 2.72
Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens (2012) 1.46
Angiotensin AT₂ receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension (2010) 1.23
Nonclassical renin-angiotensin system and renal function. Compr Physiol (2012) 1.02
Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol (2014) 0.94
Calmodulin-dependent protein kinase II/cAMP response element-binding protein/Wnt/β-catenin signaling cascade regulates angiotensin II-induced podocyte injury and albuminuria. J Biol Chem (2013) 0.92
Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair (2011) 0.87
Balance between the two kinin receptors in the progression of experimental focal and segmental glomerulosclerosis in mice. Dis Model Mech (2014) 0.83
Beneficial effects of the activation of the angiotensin-(1-7) MAS receptor in a murine model of adriamycin-induced nephropathy. PLoS One (2013) 0.81
Angiotensin II type 2 receptor correlates with therapeutic effects of losartan in rats with adjuvant-induced arthritis. J Cell Mol Med (2013) 0.81
Acute hyperglycemia rapidly stimulates VEGF mRNA translation in the kidney. Role of angiotensin type 2 receptor (AT2). Cell Signal (2010) 0.81
Perinatal Na+ overload programs raised renal proximal Na+ transport and enalapril-sensitive alterations of Ang II signaling pathways during adulthood. PLoS One (2012) 0.78
Mechanisms of disease reversal in focal and segmental glomerulosclerosis. Adv Chronic Kidney Dis (2014) 0.78
Impact of Mast Cell Chymase on Renal Disease Progression. Curr Hypertens Rev (2012) 0.78
Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging (2010) 0.77
Angiotensin III increases monocyte chemoattractant protein-1 expression in cultured human proximal tubular epithelial cells. Korean J Intern Med (2015) 0.75
Effects of combination PPARγ agonist and angiotensin receptor blocker on glomerulosclerosis. Lab Invest (2016) 0.75
Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4-/- mouse model. Dig Dis Sci (2012) 0.75
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA (2002) 12.29
Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens (1988) 3.86
Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest (1985) 2.99
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest (1986) 2.91
Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation (2001) 2.14
The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest (1997) 2.05
Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol (2005) 1.94
Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol (2006) 1.82
Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int (2000) 1.81
Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol (2004) 1.55
A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest (2003) 1.42
Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem (1997) 1.41
Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest (2009) 1.41
Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. J Mol Cell Cardiol (2004) 1.40
Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol (2003) 1.39
Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens (2005) 1.25
PPAR-gamma agonist protects podocytes from injury. Kidney Int (2007) 1.23
Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int (1998) 1.19
Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int (2000) 1.17
Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol (2001) 1.16
AT(1) and AT(2) receptors in the kidney: role in disease and treatment. Am J Kidney Dis (2000) 1.13
Progression and potential regression of glomerulosclerosis. Kidney Int (2001) 1.09
Retracted Angiotensin II type 2 receptor inhibits epidermal growth factor receptor transactivation by increasing association of SHP-1 tyrosine phosphatase. Hypertension (2001) 1.07
The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis (2000) 1.06
Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol (2002) 1.06
MAPK/AP-1-dependent regulation of PAI-1 gene expression by TGF-beta in rat mesangial cells. Kidney Int (2005) 1.04
Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int (2000) 1.03
Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol (2006) 1.01
Mitogen-activated protein kinases and activator protein 1 are required for proliferation and cardiomyocyte differentiation of P19 embryonal carcinoma cells. J Biol Chem (2002) 1.01
Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol (1998) 1.00
Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J Mol Endocrinol (2006) 1.00
Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model. Am J Physiol Renal Physiol (2003) 0.99
Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination. Am J Physiol Renal Physiol (2008) 0.98
Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice. Kidney Int (2009) 0.98
Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol (2003) 0.98
Persistent proteinuria up-regulates angiotensin II type 2 receptor and induces apoptosis in proximal tubular cells. Am J Pathol (2004) 0.98
Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol (1999) 0.97
Angiotensin II-dependent induction of AT(2) receptor expression after renal ablation. Am J Physiol Renal Physiol (2004) 0.96
Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension (2003) 0.96
Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation (2000) 0.94
Role of AT1 and AT2 receptors in regulation of MAPKs and MKP-1 by ANG II in adult cardiac myocytes. Am J Physiol (1998) 0.93
Effect of angiotensin II type 2 receptor on tyrosine kinase Pyk2 and c-Jun NH2-terminal kinase via SHP-1 tyrosine phosphatase activity: evidence from vascular-targeted transgenic mice of AT2 receptor. Biochem Biophys Res Commun (2001) 0.91
Angiotensin II type 2 receptors stimulate collagen synthesis in cultured vascular smooth muscle cells. Hypertension (2000) 0.88
Angiotensin II subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC12W cells. Mol Endocrinol (2002) 0.88
Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding. Hypertension (2004) 0.85
Attenuation of cuff-induced neointimal formation by overexpression of angiotensin II type 2 receptor-interacting protein 1. Hypertension (2009) 0.84
Regulation of vascular proteoglycan synthesis by angiotensin II type 1 and type 2 receptors. J Am Soc Nephrol (2001) 0.83
Renal fibrosis and the renin-angiotensin system. Adv Nephrol Necker Hosp (2001) 0.83
Angiotensin II modulates cellular functions of podocytes. Kidney Int Suppl (1998) 0.82
The plasminogen activator inhibitor-1 gene is induced by cell adhesion through the MEK/ERK pathway. J Biomed Sci (2003) 0.81
The genome sequence of the filamentous fungus Neurospora crassa. Nature (2003) 11.39
Sequencing of Aspergillus nidulans and comparative analysis with A. fumigatus and A. oryzae. Nature (2005) 7.74
The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol (2004) 7.38
The genome sequence of the rice blast fungus Magnaporthe grisea. Nature (2005) 6.95
Insights from the genome of the biotrophic fungal plant pathogen Ustilago maydis. Nature (2006) 5.52
The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int (2004) 4.77
The Fusarium graminearum genome reveals a link between localized polymorphism and pathogen specialization. Science (2007) 4.43
Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis (2004) 4.20
Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med (2010) 3.78
Pathologic classification of diabetic nephropathy. J Am Soc Nephrol (2010) 3.61
Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol (2006) 3.19
Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol (2003) 3.06
Lifestyle transitions in plant pathogenic Colletotrichum fungi deciphered by genome and transcriptome analyses. Nat Genet (2012) 2.92
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes (2005) 2.67
Genomics of the fungal kingdom: insights into eukaryotic biology. Genome Res (2005) 2.54
Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol (2012) 2.42
Genome sequencing and comparative transcriptomics of the model entomopathogenic fungi Metarhizium anisopliae and M. acridum. PLoS Genet (2011) 2.35
Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol (2005) 2.33
Insights into evolution of multicellular fungi from the assembled chromosomes of the mushroom Coprinopsis cinerea (Coprinus cinereus). Proc Natl Acad Sci U S A (2010) 2.30
The genome of Nectria haematococca: contribution of supernumerary chromosomes to gene expansion. PLoS Genet (2009) 2.29
Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol (2012) 2.21
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Comparative genomics yields insights into niche adaptation of plant vascular wilt pathogens. PLoS Pathog (2011) 2.13
Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice. Am J Pathol (2003) 2.05
Early school-age outcomes of late preterm infants. Pediatrics (2009) 1.96
Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int (2003) 1.94
Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol (2005) 1.94
Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest (2010) 1.90
Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes (2004) 1.85
Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol (2006) 1.82
Characterization of renal progenitors committed toward tubular lineage and their regenerative potential in renal tubular injury. Stem Cells (2012) 1.78
Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer (2010) 1.75
Podocyte injury damages other podocytes. J Am Soc Nephrol (2011) 1.75
Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int (2002) 1.69
Distinct epitopes for anti-glomerular basement membrane alport alloantibodies and goodpasture autoantibodies within the noncollagenous domain of alpha3(IV) collagen: a janus-faced antigen. J Am Soc Nephrol (2005) 1.69
Dystroglycan in the diagnosis of FSGS. Clin J Am Soc Nephrol (2009) 1.60
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Kidney Int (2012) 1.60
Renal biopsy findings among Indigenous Australians: a nationwide review. Kidney Int (2012) 1.56
Unexplained nephrotic-range proteinuria in a 38-year-old man: a case of "no change disease". Am J Kidney Dis (2004) 1.54
Validation of the Oxford classification of IgA nephropathy. Kidney Int (2011) 1.53
Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol (2005) 1.50
Distinct subpopulations of FOXD1 stroma-derived cells regulate renal erythropoietin. J Clin Invest (2016) 1.49
Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest (2002) 1.45
Malignant transformation of intrathoracic ancient neurilemmoma in a patient without Von Recklinghausen's disease. J Korean Med Sci (2003) 1.45
Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol (2004) 1.44
Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol (2005) 1.44
Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int (2005) 1.42
Endoscopic balloon dilation lithotripsy for difficult bile duct stones. Dig Dis Sci (2014) 1.39
Intrarenal dopamine deficiency leads to hypertension and decreased longevity in mice. J Clin Invest (2011) 1.38
HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. J Am Soc Nephrol (2006) 1.35
Lack of integrin alpha1beta1 leads to severe glomerulosclerosis after glomerular injury. Am J Pathol (2004) 1.33
Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics (2004) 1.31
Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol (2005) 1.31
Cell senescence in the aging kidney. J Am Soc Nephrol (2010) 1.30
Permanent genetic tagging of podocytes: fate of injured podocytes in a mouse model of glomerular sclerosis. J Am Soc Nephrol (2005) 1.28
Pathology of human diabetic nephropathy. Contrib Nephrol (2011) 1.26
Membranous nephropathy with crescents. J Am Soc Nephrol (2011) 1.25
Models of chronic kidney disease. Drug Discov Today Dis Models (2010) 1.24
Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant (2008) 1.24
The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. J Am Soc Nephrol (2009) 1.22
Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice. Atherosclerosis (2005) 1.22
Scope and mechanisms of obesity-related renal disease. Curr Opin Nephrol Hypertens (2010) 1.20
Comparative genomic analysis of human fungal pathogens causing paracoccidioidomycosis. PLoS Genet (2011) 1.20
One fungus, one name: defining the genus Fusarium in a scientifically robust way that preserves longstanding use. Phytopathology (2013) 1.19
Comparative genomics of a plant-pathogenic fungus, Pyrenophora tritici-repentis, reveals transduplication and the impact of repeat elements on pathogenicity and population divergence. G3 (Bethesda) (2013) 1.18
Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol (2012) 1.18
Immunolocalization of fibroblast growth factor-1 (FGF-1), its receptor (FGFR-1), and fibroblast-specific protein-1 (FSP-1) in inflammatory renal disease. Kidney Int (2005) 1.17
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int (2009) 1.17
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. J Clin Invest (2009) 1.14
Parietal epithelial cell activation marker in early recurrence of FSGS in the transplant. Clin J Am Soc Nephrol (2012) 1.13
Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Am J Physiol Renal Physiol (2011) 1.13
Monoclonal gammopathy: significance and possible causality in renal disease. Am J Kidney Dis (2003) 1.11
An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant (2006) 1.10
Recurrent lupus nephritis in renal transplant recipients revisited: it is not rare. Transplantation (2003) 1.07
An easily prepared hypersensitive water-soluble fluorescent probe for mercury(II) ions. Chem Commun (Camb) (2009) 1.07
CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int (2010) 1.06
Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int (2004) 1.06
Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes (2007) 1.06
Concurrent and discrete clinicopathological presentations of Wegener granulomatosis and anti-glomerular basement membrane disease. Am J Kidney Dis (2009) 1.05
Sex differences in birth defects: a study of opposite-sex twins. Birth Defects Res A Clin Mol Teratol (2005) 1.04